Results 181 to 190 of about 41,111 (239)

Status of Antibiotic Susceptibility of Polymyxin B And Colistin in the Treatment of Carbapenem Resistant Gram Negative Bacterial Infections: An Observational Study. [PDF]

JNMA J Nepal Med Assoc
Bhattarai AK, Pokharel K, Shrestha MV.
europepmc   +1 more source

A plant-derived antimicrobial peptide with multiple mechanisms of action exhibiting antibacterial and antibiofilm activities comparable to or superior to polymyxin B. [PDF]

Curr Res Microb Sci
Al Bouni MA, Lima RM, Jenei S, Tiricz H, Tímár E, Domonkos I, Kondorosi É, Endre G.   +7 more
europepmc   +1 more source

Safety and therapeutic potential evaluation of Cefotaxime plus Polymyxin B against polymyxin-carbapenem resistant Klebsiella pneumoniae in a murine model. [PDF]

PLoS One
Sturaro MC, Damaceno NDS, de Souza GHA, Echeverria JES, Cornelius EB, Pires LP, Silva PVDB, Gomes BMC, Fraga TL, Silva ON, Rossato L, Simionatto S.   +11 more
europepmc   +1 more source

Battle of polymyxin induced nephrotoxicity: Polymyxin B versus colistin [PDF]

International Journal of Antimicrobial Agents
Nephrotoxicity is the most serious and common adverse effect that limits the use of polymyxins. This study compared polymyxin E (colistin) and polymyxin B regarding drug-related nephrotoxicity.This study was conducted as a retrospective cohort study in a university hospital between January 2020 and July 2022.
Melek Kurtaran, Emre Kara, Gulcin Telli Dizman   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Synthesis of Lipid A Derivatives and Their Interactions with Polymyxin B and Polymyxin B Nonapeptide

Journal of the American Chemical Society, 2003
Lipid A is the causative agent of Gram-negative sepsis, a leading cause of mortality among hospitalized patients. Compounds that bind lipid A can limit its detrimental effects. Polymyxin B, a cationic peptide antibiotic, is one of the simplest molecules capable of selectively binding lipid A and may serve as a model for further development of lipid A ...
Ning, Yin, Ryan L, Marshall, Sannali, Matheson, Paul B, Savage   +3 more
openaire   +2 more sources

DANGER OF POLYMYXIN B

Archives of Dermatology, 1963
To the Editor : In the June, 1961, issue of theArchives of Dermatology, G. Asboe-Hansen, M.D., Copenhagen, Denmark, reported the therapeutical essay of polymyxin B (Pfizer) in a case of generalized mastocytosis. We tried this treatment, utilizing disyncran as a cover against histamine liberation, in a case of urticaria pigmentosa which had resisted ...
openaire   +3 more sources

Population Pharmacokinetics of Polymyxin B

Clinical Pharmacology & Therapeutics, 2018
Polymyxin B is used as a last treatment resort for multidrug‐resistant Gram‐negative bacterial infections. The objectives of this study were to examine the population pharmacokinetics of polymyxin B and investigate factor(s) influencing pharmacokinetic variability.
Pooja, Manchandani, Visanu, Thamlikitkul, Yanina, Dubrovskaya, Jessica T, Babic, David C, Lye, Lawrence S, Lee, Vincent H, Tam   +6 more
openaire   +2 more sources